Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.

This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

This review discusses five potential mechanisms for kidney stone formation, including urinary supersaturation, Randall's plaques, sex hormones, the microbiome, and immune responses, and reports no new results.

This practical guide introduces methods to study human dermal white adipose tissue but does not report new clinical results, emphasizing available techniques and staining protocols.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

This study reports that systemic lupus erythematosus with aplastic anemia is rare in children but highlighted serious outcomes, including a high infection rate and significant mortality, underscoring the need for vigilant management.

Raltegravir may cause hair loss in some patients.

This study demonstrated that a computational screening process can identify existing drugs and natural compounds with potential anti-COVID-19 activity, highlighting some candidates for further experimental validation.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

This review discusses the potential of using human hair proteomics for non-invasive diagnostic and forensic applications but reports no new results; the authors highlight areas needing further research.

In this study, researchers discovered that several compounds, including brequinar and 6-azauridine, exhibit significant anti-Zika virus activity using a high-throughput screen assay.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This study suggests that itraconazole may significantly improve therapy for aspergillosis, with 12 out of 15 evaluable patients responding to the treatment.

This case study presents an asthma patient with H1N1 pneumonia who developed invasive Aspergillosis despite avoiding steroids, suggesting that factors other than steroid use can contribute to IA in such patients.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This review outlines the urgent need for effective therapeutic interventions against coronaviruses, as current vaccines are challenged by virus mutations, and emphasizes developing safe, affordable, and broad-spectrum antivirals for both human and porcine coronaviruses.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

In this case report, azathioprine was linked to anagen effluvium in a 36-year-old woman after two weeks of use; hair regrowth occurred once the drug was stopped and minoxidil treatment was started.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

This study found that cepharanthine may be a promising treatment for enterovirus infections, as it offered full protection to mice against lethal EV71 challenges and reduced viral titers and pathology.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.